Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
James Healy is Director at Rapport Therapeutics. OQRO lists 4 transactions filed with the SEC under this name, the latest on Oct 30, 2026, each linked to the official Form 4.
Director
Disclosures on record
4
Companies involved
1
As of the latest filing on , James Healy reported holding 2,873,888 shares of Rapport Therapeutics (RAPP), worth about $75.2M at the last close of $26 (Nov 13, 2026), held through a summittx pinnacle master, l.p. - healthcare 3, a summittx master, spc - summittx alpha sp - healthcare 3, a summittx master, spc -summittx apex sp - healthcare 3, a sofinnova venture partners xi, l.p. In the last 12 months, James Healy bought $20.4M in 4 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Rapport Therapeutics RAPP | 2,873,888 | 25K summittx pinnacle master, l.p. - healthcare 3 · 15K summittx master, spc - summittx alpha sp - healthcare 3 · 18K summittx master, spc -summittx apex sp - healthcare 3 · 2.82M sofinnova venture partners xi, l.p | $26 | $75.2M | Oct 28, 2026 |
Is this James Healy’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Rapport TherapeuticsRAPP
4 disclosures · Oct 2026 · 4 bought
Oct 28, 2026Bought~$20Mdisclosed Oct 30
DetailsOfficial recordOct 28, 2026Bought~$146Kdisclosed Oct 30
DetailsOfficial recordOct 28, 2026Bought~$134Kdisclosed Oct 30
DetailsOfficial recordOct 28, 2026Bought~$79Kdisclosed Oct 30
DetailsOfficial recordOn the latest SEC Form 4, dated Oct 28, 2026, James Healy reported holding 2,873,888 shares of Rapport Therapeutics (RAPP), held indirectly. At the last close of $26 on Nov 13, 2026, that is about $75.2M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, James Healy reported 4 open-market purchases worth $20.4M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
James Healy bought shares on the open market in 2014, 2015, 2016, 2021, 2024 and 2026 across 9 companies. Sales in 8 of the 16 years since 2011.
In SEC filings since 2011: the latest open-market purchase is from 2026; the latest open-market sale is from 2023.
9 companies: Rapport Therapeutics (RAPP, 2024–2026), Bioage Labs (BIOA, 2024), Arrivent Biopharma (AVBP, 2024), Natera (NTRA, 2015–2023), Coherus Oncology (CHRS, 2014–2021) and others.
James Healy bought shares on the open market in 2014, 2015, 2016, 2021, 2024 and 2026 across 9 companies. Sales in 8 of the 16 years since 2011.
James Healy reported 35 open-market purchases and 19 sales since 2011; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $20.4M4×4 trades | — |
| 2024 | $30.6M23×23 trades | — |
| 2023 | — | $37.8M1×1 trade |
| 2022 | — | $91K1×1 trade |
| 2021 | $9.27M2×2 trades | $7.25M3×3 trades |
| 2019 | — | $20.1M4×4 trades |
| 2018 | — | $513K1×1 trade |
| 2016 | $3.95M1×1 trade | — |
| 2015 | $12.7M3×3 trades | — |
| 2014 | $11.3M2×2 trades | $11K1×1 trade |
| 2012 | — | $32.9M5×5 trades |
| 2011 | — | $7.42M3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
James Healy reported 21 open-market purchases and 0 sales here, 2024 to 2026.
James Healy reported 1 open-market purchase and 8 sales here, 2014 to 2021.
James Healy reported 0 open-market purchases and 8 sales here, 2011 to 2012.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
